Bristol-Myers Squibb logo

Bristol-Myers SquibbNYSE: BMY

Profile

Sector:

Healthcare

Country:

United States

IPO:

01 June 1972

Next earnings report:

06 February 2025

Last dividends:

04 October 2024

Next dividends:

N/A
$112.42 B
-34%vs. 3y high
99%vs. sector
-vs. 3y high
-vs. sector
-1%vs. 3y high
87%vs. sector
-35%vs. 3y high
41%vs. sector

Price

after hours | Tue, 05 Nov 2024 00:54:56 GMT
$55.43+$0.84(+1.54%)
$11.89 B$11.54 B
$11.89 B$1.21 B

Analysts recommendations

Institutional Ownership

BMY Latest News

5 Must Own High-Yield Dividend Stocks If Kamala Harris Wins
247wallst.com04 November 2024 Sentiment: NEUTRAL

According to 24/7 Wall St. Insights, the long political season is nearing its end.

Stock Market Rally Is 2 Years Old: 3 Passive Income Favorites Are November Bargains
247wallst.com02 November 2024 Sentiment: NEUTRAL

According to 24/7 Wall St. Insights, the ongoing surge in AI technology has led to many tech stocks being priced too high.

Bristol Myers's stock pops as earnings top estimates and company raises guidance
marketwatch.com31 October 2024 Sentiment: POSITIVE

The company claims it has made significant progress in the third quarter.

Bristol Myers Stock Rises After Earnings Beat, Guidance Hike
barrons.com31 October 2024 Sentiment: POSITIVE

The pharmaceutical company reported adjusted earnings of $1.80 per share for the third quarter, with total revenue reaching $11.9 billion.

Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
cnbc.com31 October 2024 Sentiment: POSITIVE

Bristol Myers Squibb announced that its earnings and revenue for the third quarter exceeded expectations, thanks to strong sales of its blood thinner, Eliquis, and a range of drugs that are expected to provide long-term growth. The company also increased its revenue and adjusted earnings predictions for the entire year.

Bristol-Myers Squibb Company (BMY) Q3 2024 Earnings Call Transcript
seekingalpha.com31 October 2024 Sentiment: POSITIVE

Bristol-Myers Squibb Company (NYSE:BMY) will hold its Q3 2024 Results Conference Call on October 31, 2024, at 8:00 AM ET. Key company participants include Chuck Triano, Chris Boerner, David Elkins, Adam Lenkowsky, and Samit Hirawat. Various analysts from firms like BMO Capital Markets, Goldman Sachs, and JPMorgan will also be joining the call.

Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings?
zacks.com28 October 2024 Sentiment: POSITIVE

BMY is aiming to improve its business by focusing on the successful launch of new medications. Recent positive news from regulators is also a good sign for the stock, and we suggest it to investors.

Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren
seekingalpha.com28 October 2024 Sentiment: POSITIVE

Bristol-Myers Squibb is a large American pharmaceutical company that focuses on discovering, developing, and selling drugs for different medical needs, and it is now valued at $108 billion. The company has raised its dividend for 15 years in a row, with a growth rate of 5% over the last decade. Additionally, its revenue grew from $15.9 billion in 2014 to $45 billion in 2023, reflecting a compound annual growth rate of 12.3%.

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
businesswire.com28 October 2024 Sentiment: POSITIVE

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #COBENFY--Bristol Myers Squibb will share new findings on clinical and health economics and outcomes research at the Psych Congress 2024.

Bristol Myers Squibb's Q3 Earnings Are Likely To Be Strong
seekingalpha.com25 October 2024 Sentiment: POSITIVE

Bristol Myers Squibb is still considered undervalued and has good long-term potential, even though its stock price has dropped recently and some investors are doubtful about its growth. The company had impressive results in the second quarter of FY2024, with sales of $12.20 billion and an adjusted EPS of $2.07, showing that its growth strategy is working. With a focus on oncology, cardiovascular health, and immunology, along with improving operations and expanding its product pipeline, BMY is set for future growth and recovery.

What type of business is Bristol-Myers Squibb?

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, licensing, manufacturing, marketing, and sale of biopharmaceutical products. Bristol-Myers pharmaceutical products are chemically synthesized or low molecular weight drugs for the following therapeutic areas: oncology; immunology with priorities in psoriasis, lupus, cancer, inflammatory bowel diseases, HIV; cardiovascular with priority in heart disease; fibrotic diseases of the lungs and liver; hepatitis B, C. The line of pharmaceuticals is represented by 10 trade brands. The Bristol-Myers company was registered in 1933 and essentially is the successor of a New York pharmaceutical manufacturer that has been in operation since 1887. Bristol-Myers' major manufacturing facilities are located in the United States, Puerto Rico, Ireland, France, and Italy.

What sector is Bristol-Myers Squibb in?

Bristol-Myers Squibb is in the Healthcare sector

What industry is Bristol-Myers Squibb in?

Bristol-Myers Squibb is in the Drug Manufacturers - General industry

What country is Bristol-Myers Squibb from?

Bristol-Myers Squibb is headquartered in United States

When did Bristol-Myers Squibb go public?

Bristol-Myers Squibb initial public offering (IPO) was on 01 June 1972

What is Bristol-Myers Squibb website?

https://www.bms.com

Is Bristol-Myers Squibb in the S&P 500?

Yes, Bristol-Myers Squibb is included in the S&P 500 index

Is Bristol-Myers Squibb in the NASDAQ 100?

No, Bristol-Myers Squibb is not included in the NASDAQ 100 index

Is Bristol-Myers Squibb in the Dow Jones?

No, Bristol-Myers Squibb is not included in the Dow Jones index

When was Bristol-Myers Squibb the previous earnings report?

No data

When does Bristol-Myers Squibb earnings report?

The next expected earnings date for Bristol-Myers Squibb is 06 February 2025